Combination therapies: GL-ONC1
Combination With Chemotherapy
In some difficult to treat, or particularly aggressive cancers, synergistic effects were found between GL-ONC1 and traditional chemotherapy drugs. For example, the graph below shows additive beneficial effects of GL-ONC1 in female nude mice when paired with cisplatin in a combination treatment for ovarian cancer.
Therapy of Ovarian Tumor Xenografts with GL-ONC1 & Cisplatin
The red arrow indicates the time of GL-ONC1 injection and the green arrows indicate the times when chemotherapy was administered. In the ovarian cancer study, the combination of GL-ONC1 treatment with chemotherapy resulted in significant enhancement of the antitumor therapy as compared to either treatment alone. This suggests the potential of combination therapy for difficult to treat cancers, where the chemotherapy may sensitize the tumors for even better response to oncolytic virotherapy.
Similar preclinical results involving combination therapy have been found for pancreatic cancer, as well as for mesothelioma. Such synergistic anti-tumor effects could potentially be delivered with a reduced cumulative toxicity for cancer patients.
Combination Therapy with Radiation
Genelux Corporation is actively studying the effects of integrating oncolytic virotherapy with standard radiation therapy after some interesting preclinical results showed promising synergy. Researchers evaluated the combination of focal ionizing radiation (IR) combined with systemically-delivered oncolytic vaccinia virus GL-ONC1 in mice bearing human glioma xenografts and found that irradiating glioma tumors PRIOR to administering GL-ONC1 resulted in a significant sensitization of these tumors to oncolytic virotherapy compared to those which were not previously irradiated prior to virotherapy. These findings are the basis for ongoing Genelux-sponsored human clincal trials involving a combination of vaccinia-based virotherapy, radiation therapy and chemotherapy.
Combination with Other Marketed Drugs
Enhanced Anti-tumor Effects in Pancreatic Cancer: Combination with Avastin
Pancreatic (PANC-1) tumor-bearing mice were treated with bevacizumab (AvastinÂ®) alone, GL-ONC1 alone, or GL-ONC1 in combination with bevacizumab. Genelux scientists found that Avastin alone led to slow and insignificant delays in tumor growth in comparison to untreated tumors. After injection with GL-ONC1, however, we observed the characteristic pattern resulting in continual regression over time. When viral therapy of GL-ONC1 was given in combination with the injection of bevacizumab during virus treatment, tumor growth inhibition was even greater in comparison to virus-only treatment. A treatment regime combining virotherapy with immunotherapy thus may give better results than each treatment alone and warrants further clinical testing.